Skip to main content
Roche signs companion Dx development deal with Merck
12/12/2018

Roche Holding and Merck have agreed to partner on a companion diagnostic test to identify patients eligible to receive Merck's anti-PD-1 therapy Keytruda. The immunohistochemistry test will evaluate mismatch repair deficiency in solid tumors by detecting four MMR proteins.

Full Story: